NASDAQ:EPRX

Eupraxia Pharmaceuticals (EPRX) Stock Price, News & Analysis

Eupraxia Pharmaceuticals logo
$5.81 -0.31 (-5.07%)
Closing price 11/20/2026 03:58 PM Eastern
Extended Trading
$5.71 -0.10 (-1.77%)
As of 11/20/2026 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Eupraxia Pharmaceuticals Stock (NASDAQ:EPRX)

Advanced

Key Stats

Today's Range
$5.69
▼
$6.42
50-Day Range
$5.81
▼
$9.10
52-Week Range
$5.63
▼
$9.32
Volume
361,640 shs
Average Volume
604,637 shs
Market Capitalization
$390.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.00
Consensus Rating
Moderate Buy

Company Overview

Eupraxia Pharmaceuticals is a clinical-stage biotechnology company developing treatments that use its DiffuSphere drug-delivery technology. The polymer-based platform is designed to release medicines over an extended period and deliver them locally to targeted tissues.

The company’s lead candidate, EP-104IAR, is an extended-release formulation of fluticasone propionate being developed as an injection into the knee for people with osteoarthritis. Eupraxia is also exploring applications of its delivery platform in other conditions, including eosinophilic esophagitis.

AI Generated. May Contain Errors.

Eupraxia Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
49th Percentile Overall Score

EPRX MarketRank™: 
2.45043671149 of 5 stars

Eupraxia Pharmaceuticals scored higher than 49% of companies evaluated by MarketBeat, and ranked 476th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Eupraxia Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 7 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Eupraxia Pharmaceuticals has a consensus price target of $18.00, representing about 209.8% upside from its current price of $5.81.

  • Amount of Analyst Coverage

    Eupraxia Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Eupraxia Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Eupraxia Pharmaceuticals are expected to decrease in the coming year, from ($0.86) to ($1.00) per share.

  • Price to Book Value per Share Ratio

    Eupraxia Pharmaceuticals has a P/B Ratio of 4.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    9.29% of the float of Eupraxia Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Eupraxia Pharmaceuticals has a short interest ratio ("days to cover") of 10.36, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Eupraxia Pharmaceuticals has recently decreased by 4.47%, indicating that investor sentiment is improving.
  • Dividend Yield

    Eupraxia Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Eupraxia Pharmaceuticals does not have a long track record of dividend growth.

  • News Sentiment

    Eupraxia Pharmaceuticals has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Eupraxia Pharmaceuticals this week, compared to 3 articles on an average week.
Receive EPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eupraxia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

EPRX Stock News Headlines

Cantor Fitzgerald Remains a Buy on Eupraxia Pharmaceuticals (EPRX)
CFA: Bank of America Said THIS
On January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savings account… The digital dollar is inevitable. Think about what this means... When the digital dollar goes live, every dollar you saved could suddenly be trackable at the transaction level. Imagine the worst case scenario: You’re now subject to new digital withdrawal limits and spending restrictions. Your account can be frozen remotely without court approval. But here's what Bank of America didn't say: There's still a way to protect your wealth before this digital prison locks. While everyone else gets trapped in the digital system, my research team has been positioning members outside that reach… completely under their own control. No government tracking. No withdrawal limits. No remote freezing.tc pixel
HC Wainwright Brokers Increase Earnings Estimates for EPRX
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Price Target Raised to $16.00
Eupraxia Pharmaceuticals (EPRX) Receives a Buy from Oppenheimer
See More Headlines

EPRX Stock Analysis - Frequently Asked Questions

Eupraxia Pharmaceuticals' stock was trading at $7.55 at the beginning of the year. Since then, EPRX shares have decreased by 23.0% and is now trading at $5.81.

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) released its quarterly earnings results on Tuesday, November, 10th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.03.

Eupraxia Pharmaceuticals' top institutional investors include Beutel Goodman & Co Ltd. (5.43%), Bellevue Group AG (3.86%), Cibc World Market Inc. (0.33%) and Flputnam Investment Management Co. (0.25%).

Shares of EPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/10/2026
Today
11/20/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:EPRX
Previous Symbol
NASDAQ:EPRX
CIK
1581178
Fax
N/A
Employees
49
Year Founded
2012

Price Target and Rating

High Price Target
$25.00
Low Price Target
$14.00
Potential Upside/Downside
+209.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.06)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$38.58 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-67.78%
Return on Assets
-46.73%

Debt

Debt-to-Equity Ratio
0.03
Current Ratio
12.25
Quick Ratio
12.25

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.36 per share
Price / Book
4.27

Miscellaneous

Outstanding Shares
67,240,000
Free Float
N/A
Market Cap
$390.66 million
Optionable
N/A
Beta
1.04

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (NASDAQ:EPRX) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners